Patents by Inventor Ranjeny Thomas

Ranjeny Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9561272
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 7, 2017
    Assignee: The University of Queensland
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan
  • Publication number: 20150216955
    Abstract: Disclosed are immunomodulatory agents that are useful for treating or preventing joint damage. More particularly, immunomodulators are disclosed for use in eliciting an antigen-specific tolerogenic response to an aggrecan polypeptide including citrullinated forms thereof to treat or prevent joint damage, including joint damage in subjects with early RA or incipient RA.
    Type: Application
    Filed: March 25, 2013
    Publication date: August 6, 2015
    Inventor: Ranjeny Thomas
  • Publication number: 20150202285
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Application
    Filed: March 31, 2015
    Publication date: July 23, 2015
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan
  • Patent number: 9017697
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: April 28, 2015
    Assignee: The University of Queensland
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan
  • Publication number: 20100151000
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Application
    Filed: October 12, 2007
    Publication date: June 17, 2010
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan
  • Publication number: 20060182726
    Abstract: The present invention discloses compositions and methods for antigen-specific suppression of immune responses, including primed immune responses. In particular, the invention discloses antigen-presenting cells, especially dendritic cells, whose level and or functional activity of CD40, or its equivalent, is impaired, abrogated or otherwise reduced, and their use for treating and/or preventing unwanted or deleterious immune responses including those that manifest in autoimmune disease, allergy and transplant rejection.
    Type: Application
    Filed: August 12, 2003
    Publication date: August 17, 2006
    Applicant: The University of Queensland
    Inventors: Ranjeny Thomas, Brendan O'Sullivan